Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics.

AJNR Am J Neuroradiol

From the Diagnostic Radiology Department (C.S., R.B.-F., K.A., L.N., F.E.-M.), American University of Beirut Medical Center, Beirut, Lebanon

Published: December 2018

The pathogenesis of multiple sclerosis is characterized by a cascade of pathobiologic events, ranging from focal lymphocytic infiltration and microglia activation to demyelination and axonal degeneration. MS has several of the hallmarks of an inflammatory autoimmune disorder, including breakdown of the BBB. Gadolinium-enhanced MR imaging is currently the reference standard to detect active inflammatory lesions in MS. Knowledge of the patterns and mechanisms of contrast enhancement is vital to limit the radiologic differential diagnosis in the staging and evaluation of MS lesion activity. The aim of this review was the following: 1) to outline the pathophysiology of the effect of lymphocyte-driven inflammation in MS, 2) to describe the effects of gadolinium on the BBB and glymphatic system, and 3) to describe gadolinium enhancement patterns and artifacts that can mimic lesions in MS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655403PMC
http://dx.doi.org/10.3174/ajnr.A5773DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
8
gadolinium multiple
4
sclerosis vessels
4
vessels barriers
4
barriers brain
4
brain glymphatics
4
glymphatics pathogenesis
4
pathogenesis multiple
4
sclerosis characterized
4
characterized cascade
4

Similar Publications

Objectives: This case series describes adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.

Methods: Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.

View Article and Find Full Text PDF

Inflammatory proteins related to depression in multiple sclerosis: A systematic review and meta-analysis.

Brain Behav Immun Health

February 2025

Mood and Anxiety Disorders Lab, Melbourne School of Psychological Sciences, University of Melbourne, Victoria, Australia.

Background: Up to 50% of individuals with multiple sclerosis (MS) experience depression. Depression has been accompanied by increases in inflammatory proteins. This meta-analysis summarized the data on inflammatory protein concentrations and level of depression in individuals with MS.

View Article and Find Full Text PDF

Multiple sclerosis (MS) is a chronic central nervous system (CNS) disease with demyelinating inflammatory characteristics. It is the most common nontraumatic and disabling disease affecting young adults. The incidence and prevalence of MS have been increasing.

View Article and Find Full Text PDF

Multiple sclerosis (MS) affects 2.8 million people worldwide. Although the cause is unknown, various risk factors might be involved.

View Article and Find Full Text PDF

Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative disease affecting the brain and spinal cord. Genetic studies have identified many risk loci, that were thought to primarily impact immune cells and microglia. Here, we performed a multi-ancestry genome-wide association study with 20,831 MS and 729,220 control participants, identifying 236 susceptibility variants outside the Major Histocompatibility Complex, including four novel loci.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!